CytoDyn Inc. (OTCMKTS:CYDY - Get Free Report) shares traded down 2.3% during trading on Friday . The stock traded as low as $0.33 and last traded at $0.34. 1,693,086 shares changed hands during trading, a decline of 51% from the average session volume of 3,449,711 shares. The stock had previously closed at $0.35.
CytoDyn Price Performance
The business's 50-day moving average is $0.29 and its two-hundred day moving average is $0.22. The firm has a market cap of $437.14 million, a P/E ratio of -35.00 and a beta of 1.15.
CytoDyn Company Profile
(
Get Free Report)
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Read More
Before you consider CytoDyn, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytoDyn wasn't on the list.
While CytoDyn currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
